Daniel Moore, MD
Hematology & Oncology · Tacoma, WANPI 1528054228
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $329 of the $395 with a category attached, or 83.3%. Reflexion Medical, Inc. accounts for 83.3% of it on its own, with 4 other manufacturers making up the rest. 2022 is the largest year on record at $329, more than ten times the $19 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 5 payments — averaging $79.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reflexion Medical, Inc.$329
- Myovant Sciences Inc.$24
- Genentech USA, Inc.$19
- Gilead$12
- Epizyme, Inc.$12
Across 10 payments — averaging $13,394 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$134K
What the payments were for
- Travel & lodging$32983%
- Food & beverage$195%
- Education$4712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reflexion Medical, Inc. | 1 | $329 |
| Myovant Sciences Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$395 in reported general payments places this provider in the 35th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 31 | $542,668 |
| RevlimidLenalidomide | 18 | $436,365 |
| Lenalidomide | 15 | $228,720 |
| XtandiEnzalutamide | 12 | $174,730 |
| BrukinsaZanubrutinib | 18 | $166,929 |
| EliquisApixaban | 56 | $74,016 |
| XareltoRivaroxaban | 28 | $36,490 |
| OrgovyxRelugolix | 12 | $33,478 |
| CreonLipase/Protease/Amylase | 11 | $9,661 |
| Abiraterone Acetate | 34 | $6,064 |
| ValacyclovirValacyclovir Hcl | 35 | $2,834 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $2,429 |
| Ketoconazole | 13 | $1,991 |
| Testosterone | 27 | $1,752 |
| Oxycodone Hcl | 68 | $1,255 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tacoma
- Jorge ChavesTacoma$27K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.